abbvie glp-1 receptor agonist weight management diabetes treatments Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Agonists: A Multidisciplinary Expert Consensus GLP-1-based therapies for type 2

Survodutide targets the liver, and the class keeps showing cardiometabolic benefit

Glucagon, secreted by alpha cells in the pancreas, is an important hormone that promotes the release of glucose from the liver into the bloodstream (Robertson, 2023)

National Center for Chronic Disease Prevention And Health Promotion

At the end of the trial, mean weight loss of 4.4% is reported in the combination group, compared to 1.6% for placebo

The number of beneficiaries eligible for the Medicare GLP-1 Bridge is unknown, but a previous KFF analysis estimated that close to 14 million Medicare beneficiaries had a diagnosis of overweight or obesity in 2020 (BMI of 25-29.9 and 30 or more, respectively), though applying the specific criteria that determine eligibility for the Medicare GLP-1 Bridge would reduce that number